# OnCo record cardio-oncology-risk-assessment-and-cardiac-surveillance (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "cardio-oncology-risk-assessment-and-cardiac-surveillance" ;
  schema:name "Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment"@en ;
  schema:alternateName "cardio-oncology baseline assessment"@en, "echocardiogram during trastuzumab"@en, "anthracycline cardiotoxicity monitoring"@en, "HFA-ICOS risk score"@en, "cancer therapy-related cardiac dysfunction"@en, "cardiac monitoring in cancer survivors"@en ;
  schema:description "Some cancer treatments, such as anthracyclines (doxorubicin, epirubicin) and trastuzumab, can weaken the heart. Before they start, your team should check your heart risk, usually with blood pressure, blood tests, an ECG and a heart scan, repeated during treatment; a fall in heart function does not always mean stopping. Afterwards, tell any doctor about new breathlessness, swelling or chest pain."@en ;
  schema:url <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "cardio-oncology", "survivorship" ;
  onco:related <https://onco.cc/key-papers/paper-lyon-eur-heart-j/>, <https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/strain-echocardiography-gls/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/trastuzumab-cardiotoxicity/>, <https://onco.cc/terms/anthracycline/> .